



Neuren wins NZ Biotechnology Company of the Year Award

Tuesday 4 October 2005: Neuren Pharmaceuticals (ASX: NEU) today announced that it has won the 2005 Biotechnology Company of the Year Award sponsored by NZ Bio, New Zealand's biotechnology industry organisation.

The awards are open to biotechnology/life sciences companies at any stage of business development. Entries are judged on aspects of demonstrated skill/success in proprietary technology, business development, and entrepreneurial strategy.

The judges looked at intellectual property assets, partnerships, collaborations and licensing deals, progress towards building an internationally competitive management team, regulatory approval status, achievement of development milestones and revenue growth.

The judges commented that: "Neuren Pharmaceuticals is targeting the prevention of brain damage by developing drugs for neural protection. With a strong cash position having raised AU\$15 million on the ASX, the company has developed a wide IP portfolio and a number of products in the pipeline."

The judges were very impressed with the milestones Neuren has demonstrated and the progress the company was continuing to make. The judges added that as a consequence, the US Food and Drug Administration has allowed Neuren to accelerate its clinical development program for Glypromate[®] so that Neuren can conduct a Phase 3 trial next year.

Mr David Clarke, CEO of Neuren said: "It is always great to get recognition of our progress. The past year has been very productive and we expect an even busier period ahead, with the completion of our Phase 2 trial and the forthcoming Phase 3 trial for Glypromate[®]."

About Glypromate[®]

Glypromate[®] is a naturally occurring compound that Neuren believes is produced as part of the brain's response to stress and injury. Glypromate[®] has been shown to act by multiple pathways to protect brain tissue from injury. Glypromate[®] is Neuren's lead drug. It and related compounds are candidates for treatment of conditions caused by chronic or acute brain injury.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of neuroprotection and metabolic disorders. The Neuren portfolio consists of five product families, targeting markets with large unmet needs and limited competition. Neuren has two lead, clinical candidates, Glypromate[®] and NNZ-2566, presently in development to treat a range of acute neurological conditions. Neuren has commercial and development partnerships, including with Pfizer, the US Army's Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren's website at www.neurenpharma.com



Contact details

Company	Media and investor relations
David Clarke CEO of Neuren T: 1800 259 181 (Australia) T: +64 9 3 367 7167 ext 82308(New Zealand) M: +64 21 988 052	Rebecca Piercy Buchan Consulting T: +61 3 9866 4722 M: +61 422 916 422